Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Cash from Financing Activities (2016 - 2025)

Pediatrix Medical (MD) has disclosed Cash from Financing Activities for 17 consecutive years, with -$68.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 1282.99% to -$68.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$107.5 million, a 642.11% decrease, with the full-year FY2025 number at -$107.5 million, down 642.11% from a year prior.
  • Cash from Financing Activities was -$68.6 million for Q4 2025 at Pediatrix Medical, down from -$28.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q1 2023 to a low of -$761.7 million in Q1 2021.
  • A 5-year average of -$69.8 million and a median of -$17.3 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 224.62% in 2021, then tumbled 63000.76% in 2022.
  • Pediatrix Medical's Cash from Financing Activities stood at $825000.0 in 2021, then plummeted by 10559.27% to -$86.3 million in 2022, then surged by 94.5% to -$4.7 million in 2023, then fell by 4.55% to -$5.0 million in 2024, then plummeted by 1282.99% to -$68.6 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Cash from Financing Activities are -$68.6 million (Q4 2025), -$28.6 million (Q3 2025), and -$4.3 million (Q2 2025).